Targretin (bexarotene) : Ligand Pharmaceuticals : Retinoid

Targretin Fails to Meet Primary or Secondary Endpoints in Pivotal Trials for NSCLC (Ligand)
Press release announcing that Targretin (bexarotene) did not meet the endpoints of improved overall survival and projected two-year survival in Phase III randomized trials. The studies (SPIRIT I & SPIRIT II) were designed to evaluate whether adding Targretin to front-line cisplatin/vinorelbine or carboplatin/paclitasel chemotherapy extends the survival of patients with advanced NSCLC (stage IIIB with pleural effusion or stage IV). Targretin will continue to be evaluated for its potential to benefit NSCLC patients in the second or third line settings. [3/05]

Emerging Role of Rexinoids in NSCLC: Focus on Bexarotene (The Oncologist)
Explains the rationale for using rexinoids to treat cancer. Reviews past and current studies of bexarotene (Targretin) for the treatment of NSCLC. Concludes that Targretin shows promise for the treatment of NSCLC, citing the survival benefit demonstrated in early studies as well as the generally acceptable level of toxicity - specific known side effects are discussed. Notes that results from the ongoing Phase III trials will elucidate the role of Targretin in the treatment of NSCLC. [1/05]

SPIRIT I & II Pivotal Studies of Targretin IN NSCLC (Ligand Pharmaceuticals)
Manufacturer's press release provides update and answers to frequently asked questions on the status of SPIRIT I & SPIRIT II, two Phase III studies of Targretin (bexarotene) capsules in front-line combination therapy to treat advanced NSCLC. [1/05]

Targretin (bexarotene) - Recent MEDLINE Abstracts